About CanSino Biologics
CanSino Biologics is a company based in Tianjin (China) founded in 2009 by Helen Huihua Mao, Tao Zhu, Dongxu Qiu, and Xuefeng Yu.. CanSino Biologics has raised $105.43 million across 4 funding rounds from investors including Gates Foundation, Qiming Venture Partners and Gopher Assets. The company has 1,100 employees as of December 31, 2024. CanSino Biologics operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
- Headquarter Tianjin, China
- Employees 1100 as on 31 Dec, 2024
- Founders Helen Huihua Mao, Tao Zhu, Dongxu Qiu, Xuefeng Yu
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cansino Biologics, Inc. Class A
-
Annual Revenue
$114.55 M (USD)139.49as on Dec 31, 2024
-
Net Profit
$-51.91 M (USD)74.45as on Dec 31, 2024
-
EBITDA
$-25.32 M (USD)87.97as on Dec 31, 2024
-
Total Equity Funding
$105.43 M (USD)
in 4 rounds
-
Latest Funding Round
$2 M (USD), Post-IPO
Oct 25, 2023
-
Investors
Gates Foundation
& 6 more
-
Employee Count
1100
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CanSino Biologics
CanSino Biologics is a publicly listed company on the SSE with ticker symbol 688185 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of CanSino Biologics
CanSino Biologics has successfully raised a total of $105.43M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $2.0M
-
First Round
First Round
(16 Sep 2013)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - CanSino Biologics | Valuation |
investors |
|
| Apr, 2017 | Amount | Series C - CanSino Biologics | Valuation | SDIC Innovation | |
| Oct, 2015 | Amount | Series B - CanSino Biologics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CanSino Biologics
CanSino Biologics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Qiming Venture Partners and Gopher Assets. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Private equity firm investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CanSino Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CanSino Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cansino Biologics Comparisons
Competitors of CanSino Biologics
CanSino Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cansino Biologics
Frequently Asked Questions about CanSino Biologics
When was CanSino Biologics founded?
CanSino Biologics was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Where is CanSino Biologics located?
CanSino Biologics is headquartered in Tianjin, China.
Who is the current CEO of CanSino Biologics?
Xuefeng Yu is the current CEO of CanSino Biologics. They have also founded this company.
Is CanSino Biologics a funded company?
CanSino Biologics is a funded company, having raised a total of $105.43M across 4 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Sep 16, 2013.
How many employees does CanSino Biologics have?
As of Dec 31, 2024, the latest employee count at CanSino Biologics is 1,100.
What is the annual revenue of CanSino Biologics?
Annual revenue of CanSino Biologics is $114.55M as on Dec 31, 2024.
What does CanSino Biologics do?
Developer of vaccines for the treatment of infectious diseases. It is specialized in developing and manufacturing a series of vaccine products, including pneumonia protein vaccines, pertussis vaccines, and recombined tuberculosis vaccines.
Who are the top competitors of CanSino Biologics?
CanSino Biologics's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Is CanSino Biologics publicly traded?
Yes, CanSino Biologics is publicly traded on SSE under the ticker symbol 688185.
Who are CanSino Biologics's investors?
CanSino Biologics has 7 investors. Key investors include Gates Foundation, Qiming Venture Partners, Gopher Assets, Fortune Capital, and Lilly Asia Ventures.
What is CanSino Biologics's ticker symbol?
The ticker symbol of CanSino Biologics is 688185 on SSE.